Expiration date: 05/2024
Composition and form of issue
Etoposide-Teva-solution for concentrated infusions:
1 ml contains etoposide 20 mg, in vials of 5, 10, 20, 25 and 50 ml.
Antitumor agent. Etoposide-Teva is a semisynthetic derivative of podophyllotoxin. The mechanism of action is associated with inhibition of topoisomerase II. Inhibits mitosis, blocks cells in The s-G2-interphase of the cell cycle, in higher doses acts in the G2-phase. Cytotoxic action against normal healthy cells is observed only when using etoposide in high doses.
Germinogenic tumors (testicular tumors, choriocarcinoma), ovarian cancer, small cell and non-small cell lung cancer, lymphogranulomatosis, non-Hodgkin's lymphoma, stomach cancer (for monotherapy and as part of combination therapy), Ewing's sarcoma, Kaposi's sarcoma, neuroblastoma, breast cancer (with liver metastases, in the pleura), acute non-lymphoblastic leukemia, mesothelioma.
Severe myelodepression, severe liver and kidney dysfunction, pregnancy, children under 2 years of age, hypersensitivity to podophylline or its derivatives.
From the hematopoietic system: leukopenia, anemia, rarely - thrombocytopenia.
From the digestive system: nausea, vomiting, rarely - anorexia, mucositis, diarrhea, when used in high doses - toxic reactions from the liver.
From the Central and peripheral nervous system: drowsiness, fatigue, damage to the peripheral nervous system.
On the part of metabolism: hyperuricemia, when using high doses - metabolic acidosis.
From the cardiovascular system: tachycardia, hypotension.
From the reproductive system: azoospermia, amenorrhea.
Allergic reactions: chills, fever, bronchospasm.
Dermatological reactions: alopecia.
Dosage and administration
When choosing the route of administration, regime and doses in each individual case should be guided by the data of the literature. The dosage regimen of Etoposide-TeV is established depending on the chemotherapy regimen used (when choosing a dose, the myelosuppressive effect of other drugs in combination, as well as the effect of previous radiation therapy and chemotherapy should be taken into account). In / drip (dissolved in 0.9% NaCl solution), for 30-60 min. Etoposid-Teva is prescribed in the following doses: 1) 100 mg/sqm/day 1 through day 5, with povtorim cycles every 3-4 weeks, 2) 100-125 mg/sq m in 1, 3, 5 days, courses repeated every 3 weeks, and 3) when administered at 50 mg/sq m daily for 21 days, with repeat cycles every 4 weeks or 100-200 mg/m for 5 consecutive days every 3 weeks. Repeated courses are carried out only after the normalization of peripheral blood. Before I/V diluted in 250 ml 0.9% NaCl solution or 5% dextrose solution to a final concentration of 0.2-0.4 mg / ml. Avoid contact with the buffer aqueous solutions with pH above 8.
Storage conditions and shelf life
The drug should be stored out of reach of children at a temperature not exceeding 20°C.